Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Melanoma

rosiglitazone has been researched along with Melanoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goepfert, C; Hafner, J; Jandus, C; Levesque, MP; Loyon, R; Mastelic-Gavillet, B; Meylan, P; Michalik, L; Moret, C; Moser, H; Nguyen, TN; Pich, C; Romero, P; Trang, BK1
Beaumont, KA; Boyle, GM; Cook, AL; Muscat, GE; Parsons, PG; Smit, DJ; Smith, AG; Sturm, RA; Thurber, AE1
Berenz, A; Haugen, BR; Hays, WR; Klopper, JP; Loi, M; Pugazhenthi, U; Said, S; Sharma, V1
Dahl, A; Freudlsperger, C; Hoffmann, J; Reinert, S; Schumacher, U1
Füzesi, L; Krüger, U; Middel, P; Mössner, R; Neumann, C; Reich, K; Schinner, S; Schulz, U1

Other Studies

5 other study(ies) available for rosiglitazone and Melanoma

ArticleYear
Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth.
    Cancer research, 2018, 11-15, Volume: 78, Issue:22

    Topics: Angiogenesis Inducing Agents; Animals; Carcinogenesis; Cell Line, Tumor; Fibroblasts; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Leukocytes, Mononuclear; Macrophages; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Monocytes; Neoplasm Metastasis; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Paracrine Communication; PPAR gamma; Rosiglitazone; Skin Neoplasms; Stromal Cells; T-Lymphocytes

2018
PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
    The international journal of biochemistry & cell biology, 2009, Volume: 41, Issue:4

    Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Chlorocebus aethiops; Chromans; COS Cells; Halofenate; Humans; Melanoma; PPAR gamma; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Troglitazone; Wnt Proteins

2009
Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
    Molecular cancer, 2009, Mar-06, Volume: 8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Bexarotene; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Ligands; Melanoma; Mice; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; Retinoids; RNA, Small Interfering; Rosiglitazone; Tetrahydronaphthalenes; Thiazolidinediones; Xenograft Model Antitumor Assays

2009
Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells.
    Phytotherapy research : PTR, 2010, Volume: 24, Issue:9

    Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Drug Synergism; Drug Therapy, Combination; Humans; Melanoma; Phytotherapy; Plant Extracts; PPAR gamma; Ribosome Inactivating Proteins, Type 2; Rosiglitazone; Thiazolidinediones; Toxins, Biological; Viscum album

2010
Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.
    The Journal of investigative dermatology, 2002, Volume: 119, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Dose-Response Relationship, Drug; Fibrinolytic Agents; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Melanoma; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Skin Neoplasms; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured

2002